14-minute MRx scan maps 20+ brain biomarkers without contrast
University of Illinois researchers developed multiplexed MRI to map more than 20 brain biomarkers in a single scan using standard clinical MRI systems.
University of Illinois Urbana-Champaign researchers have developed multiplexed MRI, an acquisition and processing method that can map more than 20 brain biomarkers in a single noncontrast scan. The work was published in Nature.
MRx uses an AI-powered framework to produce high-resolution multiparametric maps of structural, physiological, and molecular brain markers. Researchers demonstrated the technique in brain tumors and multiple sclerosis lesions.
A whole-brain MRx scan can be completed in approximately 14 minutes, according to the university. Researchers said that is within a clinically acceptable time frame and shorter than conventional multicontrast clinical MRI protocols, which can take up to 1 hour.
Nature’s abstract states that MRx can obtain a large set of quantitative biomarkers of the whole brain in standard clinical settings. The authors also reported that these biomarkers could define a tissue state index for disease subtyping and lesion characterization in tumors and MS.
Rong Guo, PhD, a coauthor and senior scientist at Siemens Healthineers, said MRx measures multiple markers “without the need for contrast agents.”
University researchers said the biomarkers provide information related to tissue metabolism, neurotransmission, physiological function, and structural characteristics. The technique may support research into early detection, diagnosis, prognosis, and treatment monitoring for brain diseases, according to the university.
The study, “Multiplexed magnetic resonance imaging,” was authored by Yudu Li, Rong Guo, Yibo Zhao, Wen Jin, Ziwen Ke, Liang Chen, Xiangjun Chen, Weijun Tang, Yao Li, and Zhi-Pei Liang.
Company:MRX
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Pediatric ED imaging gaps persist by race and insurance status
A cohort study of 857,034 pediatric ED visits found that stronger hospital pediatric capability was not associated with narrower imaging-use differences by race, ethnicity, or insurance status.
Study finds wide variation in chest X-ray AI performance
A head-to-head study of 7 commercial AI devices found sensitivity ranged from 20.8% to 77.8% for lung cancer detection on chest X-rays.
MRI radiomics model predicts colorectal cancer subtype
The multicenter study found an MRI-based machine-learning radiomics score predicted CMS4 colorectal cancer and stratified recurrent metastasis risk.
Contrast tied to higher AKI risk in neonatal ICU study
The retrospective study found higher acute kidney injury rates in neonates exposed to iodinated contrast media, although most cases were stage 1.
Quantum BioPharma reports early PET tracer signal in MS study
The ongoing MGH study is evaluating [18F]3F4AP PET imaging for demyelinated neurons with intact axons in patients with multiple sclerosis.
Cochrane updates prostate cancer screening review
The updated review found PSA screening likely reduces prostate cancer deaths, but evidence remains unclear for newer screening strategies combining PSA, kallikrein testing, and MRI.
Stage 4 breast cancer diagnoses rise over decade
A cohort study of 761,471 people found de novo stage 4 breast cancer incidence increased by 1.2% per year from 2010 to 2021.
SIR backs genicular artery embolization for knee osteoarthritis
The Society of Interventional Radiology issued a position statement supporting genicular artery embolization for symptomatic knee osteoarthritis.
Fluoride, lead co-exposure linked to lower youth BMD
Researchers analyzed NHANES data from 2,378 U.S. children and adolescents who underwent DEXA scans from 2013 to 2016.
Stanford receives $3.9M ARPA-H grant for MR lymphangiography
Stanford Medicine received up to $3.9M from ARPA-H to advance MR lymphangiography. Andreas Loening, MD, PhD, will lead work on faster scans, lymphatic-specific contrast agents, and contrast-free flow assessment.
Bayer PET tracer meets cardiac amyloidosis endpoints
Bayer reported positive topline phase 3 REVEAL results for I-124 evuzamitide, an investigational PET/CT radiotracer for suspected cardiac amyloidosis. The study met its sensitivity and specificity endpoints.
PSMA PET linked to more intensive prostate cancer treatment
A national claims analysis found that PSMA PET use was associated with higher initiation of androgen receptor pathway inhibitors and systemic therapy in newly diagnosed advanced prostate cancer.